Purpose c-MET (MET) receptor activation is associated with poor prognosis and epidermal
growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) resistance in non–small-cell …

Purpose Tivantinib, a MET receptor tyrosine kinase inhibitor, demonstrated increased
anticancer activity in preclinical and early clinical studies when combined with erlotinib. Our …

Molecular targeted therapies, such as the epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors (TKIs), provide a different mechanism of action from chemotherapy and can …

Purpose Histone deacetylase inhibitors (HDACis) have been shown to overcome resistance
to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) linked to …

Abstract Introduction The phase II JO25567 study compared the efficacy and safety of
erlotinib plus bevacizumab vs. erlotinib alone as first-line therapy for advanced epidermal …

Purpose To investigate the efficacy of erlotinib versus docetaxel in previously treated
patients with advanced non–small-cell lung cancer (NSCLC) in an epidermal growth factor …

We present the rationale and design for MARQUEE, a phase III, randomized, double-blind,
placebo-controlled study of ARQ 197 plus erlotinib versus placebo plus erlotinib in …

Background A previous randomized phase II study demonstrated that the addition of a c-Met
inhibitor tivantinib to an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor …

Purpose Erlotinib is clinically effective in patients with non–small-cell lung cancer (NSCLC)
who have adenocarcinoma, are never or limited former smokers, or have EGFR mutant …

Background Erlotinib is registered for treatment of all patients with advanced non-small-cell
lung cancer (NSCLC). However, its efficacy for treatment of patients whose tumours are …